---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-25-000164"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:17:55.118230+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Recursion appoints Najat Khan as CEO effective Jan 1, 2026; Q3 net loss $162.3M

## Summary
- Najat Khan succeeds Chris Gibson as CEO and President effective Jan 1, 2026; Gibson becomes Chairman.
- Khan's base salary set at $680K; receives $1M equity now and expected additional $7.5M equity.
- Q3 revenue $5.2M (down from $26.1M); net loss $162.3M (vs $95.8M); R&D spend $121.1M.
- Cash ~$785M as of Oct 9, 2025; runway through end-2027; raised $387.5M from ATM facility.
- Second microglia phenomap accepted by Roche/Genentech triggers $30M milestone; total partner payments exceed $500M.

## SEC filing metadata
- accession: 0001601830-25-000164
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/0001601830-25-000164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/rxrx-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-25-000164
- JSON: https://secwatch.observer/filing/0001601830-25-000164.json
- Plain text: https://secwatch.observer/filing/0001601830-25-000164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.